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Increasing the dose intensity of chemotherapy by more 
frequent administration or sequential scheduling: 
a patient-level meta-analysis of 37 298 women with early 
breast cancer in 26 randomised trials
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)*
Summary
Background Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving 
individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance 
efficacy.
Methods To clarify the relative benefits and risks of dose-intense and standard-schedule chemotherapy in early breast 
cancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, 
and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy. The 
primary outcomes were recurrence and breast cancer mortality. Standard intention-to-treat log-rank analyses, stratified 
by age, nodal status, and trial, yielded dose-intense versus standard-schedule first-event rate ratios (RRs).
Findings Individual patient data were provided for 26 of 33 relevant trials identified, comprising 37 298 (93%) of 
40 070 women randomised. Most women were aged younger than 70 years and had node-positive disease. Total cytotoxic 
drug usage was broadly comparable in the two treatment arms; colony-stimulating factor was generally used in the more 
dose-intense arm. Combining data from all 26 trials, fewer breast cancer recurrences were seen with dose-intense than 
with standard-schedule chemotherapy (10-year recurrence risk 28·0% vs 31·4%; RR 0·86, 95% CI 0·82–0·89; p<0·0001). 
10-year breast cancer mortality was similarly reduced (18·9% vs 21·3%; RR 0·87, 95% CI  0·83–0·92; p<0·0001), as was 
all-cause mortality (22·1% vs 24·8%; RR 0·87, 95% CI 0·83–0·91; p<0·0001). Death without recurrence was, if anything, 
lower with dose-intense than with standard-schedule chemotherapy (10-year risk 4·1% vs 4·6%; RR 0·88, 95% CI 
0·78–0·99; p=0·034). Recurrence reductions were similar in the seven trials (n=10 004) that compared 2-weekly 
chemotherapy with the same chemotherapy given 3-weekly (10-year risk 24·0% vs 28·3%; RR 0·83, 95% CI 0·76–0·91; 
p<0·0001), in the six trials (n=11 028) of sequential versus concurrent anthracycline plus taxane chemotherapy (28·1% 
vs 31·3%; RR 0·87, 95% CI 0·80–0·94; p=0·0006), and in the six trials (n=6532) testing both shorter intervals and 
sequential administration (30·4% vs 35·0%; RR 0·82, 95% CI 0·74–0·90; p<0·0001). The proportional reductions in 
recurrence with dose-intense chemotherapy were similar and highly significant (p<0·0001) in oestrogen receptor 
(ER)-positive and ER-negative disease and did not differ significantly by other patient or tumour characteristics.
Interpretation Increasing the dose intensity of adjuvant chemotherapy by shortening the interval between treatment 
cycles, or by giving individual drugs sequentially rather than giving the same drugs concurrently, moderately reduces 
the 10-year risk of recurrence and death from breast cancer without increasing mortality from other causes.
Funding Cancer Research UK, Medical Research Council.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Among women with early breast cancer, standard 
combination chemotherapy that includes an anthra cycline 
and taxane reduces breast cancer mortality by about a 
third compared with no chemotherapy.1 The proportional 
reduction is largely independent of oestrogen receptor 
(ER) status, nodal status, or other classical tumour 
characteristics, so the absolute benefit from chemotherapy 
for an individual woman depends mainly on her absolute 
risk of breast cancer recurrence and death.
Trials investigating newer cytotoxic agents for breast 
cancer have not yet identified any classes that are clearly 
superior to taxanes and anthracyclines,2–4 but the optimal 
dosage and timing of these two drugs is still unclear. Cell 
biology and cytokinetic modelling suggest that increasing 
dose intensity (ie, the amount of drug delivered per unit 
time)5 could enhance tumour cell kill, reduce tumour 
regrowth between cycles, and thereby further improve 
the likelihood of cure.6,7 However, studies comparing 
anthra cycline doses have shown no apparent benefit from 
escalating beyond standard doses,8 although lesser benefit 
is seen with doses below this threshold,9–11 suggesting that 
dose escalation alone cannot kill all tumour cells. This 
might be due to the non-linearity of dose–response or 
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clonal variation in chemotherapy sensitivity.12 Two ways to 
increase dose intensity without escalating total dose are to 
shorten the interval between treatment cycles (dose-dense 
chemo therapy) or to administer individual drugs in 
sequence (sequential scheduling), which allows higher 
doses to be used in each cycle than is possible with 
combined administration of the same drugs (concurrent 
scheduling).7
For most multiple-agent chemotherapy regimens, it 
was initially not possible to administer treatments with 
intervals shorter than the standard 3-weekly or 4-weekly 
cycles because of unacceptable toxicity. However, the 
introduction of better supportive treatments, particularly 
granulocyte colony-stimulating factor (G-CSF), has 
allowed investigation of dose-dense and other dose-
intensification schedules. To help clarify the relative 
benefits and risks of dose-intense and standard-schedule 
chemotherapy, we did collaborative meta-analyses of 
individual patient-level data from randomised trials that 
compared 2-weekly dose-dense chemotherapy with 
standard 3-weekly or 4-weekly administration, and trials 
of sequential versus concurrent anthracycline and taxane 
chemotherapy.
Methods
Search strategy and selection criteria
Methods of identifying trials, data collection, checking, 
analysis, and presentation were as described in previous 
reports from the Early Breast Cancer Trialists’ Collaborative 
Group (EBCTCG),1,13–15 and conform with the PRISMA-
IPD statement.16 Trials of adjuvant or neoadjuvant 
chemo therapy were eligible if they began before 2008 and 
randomly assigned women either to chemotherapy with 
shorter intervals between cycles (dose-dense) or to 
identical or similar-dose chemotherapy with standard 
intervals between cycles (3-weekly or 4-weekly), or to 
anthracycline and taxane-based chemo therapy given 
sequentially versus concurrently (appendix pp 34–43). 
Trials of dose fraction ation (eg, giving drugs once weekly 
at approximately a third of the dose used in a 3-weekly 
regimen)17 were not eligible. In general, dose-intense 
regimens included primary prophylaxis with G-CSF. 
Information was sought from trial groups during 2015–18 
for each individual patient on randomisation date, 
allocated treatment, age, menopausal status, body-mass 
index (BMI), tumour diameter, grade, histology, spread 
to locoregional lymph nodes, oestrogen receptor (ER) 
status, progesterone receptor (PR) status, HER2 status, 
proliferation index, dates and sites of any breast cancer 
recurrence or other second primary cancer, and the date 
and underlying cause of any death without recurrence.
Primary outcomes were any recurrence of invasive 
breast cancer (distant, locoregional, or new primary in the 
contralateral breast), breast cancer mortality (by log-rank 
subtraction), death without recurrence, and all-cause 
mortality. Prespecified primary subgroup investigations 
were by site of recurrence, method of dose intensification, 
use of taxane, number of escalated cycles (≤4 vs ≥6), age, 
ER and PR status, nodal status, tumour diameter, grade, 
histology (ductal, lobular), HER2 status, proliferation 
index (Ki-67 <10%, 10–19%, or ≥20%), and follow-up 
period (years 0–1, 2–4, 5–9, or ≥10).
Research in context
Evidence before this study
Previous meta-analyses from the Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG) have shown that anthracycline 
and taxane-based combination chemotherapy reduces the risk 
of breast cancer mortality by about a third compared with no 
chemotherapy. Cell biology suggests that increasing the dose 
intensity of chemotherapy—for example, by shortening the 
interval between treatment cycles or by giving higher doses of 
drugs individually rather than lower doses concurrently—might 
improve outcomes; various clinical trials have been designed to 
test this hypothesis. The EBCTCG’s ongoing extensive searches 
of bibliographic databases including MEDLINE, Embase, 
the Cochrane Library, and meeting abstracts up to 
March, 2018, identified 33 trials that compared dose-intensive 
versus standard schedule chemotherapy, but these trials used a 
wide range of chemotherapy combinations and schedules, 
with inconsistent results reported.
Added value of this study
This collaborative meta-analysis collated, checked, and analysed 
individual patient-level data from 37 298 patients in 26 trials, 
comprising 93% of all patients in identified studies of dose 
intensification. In seven trials comparing chemotherapy 
administered every 2 weeks versus the same drugs, doses, 
and number of cycles administered every 3 weeks, the 
dose-dense 2-weekly schedule reduced the risk of breast cancer 
recurrence by 17% compared with standard treatment. 
The absolute reduction in the 10-year risk of breast cancer 
recurrence was 4·3%, with a 2·8% reduction in the 10-year risk of 
dying from breast cancer, and no increase in non-breast cancer 
deaths. Other dose-intensification strategies of administering 
individual drugs sequentially rather than concurrently showed 
similar benefits. The proportional reductions in recurrence were 
similar for oestrogen receptor (ER)-positive and ER-negative 
tumours and did not differ significantly by other patient or 
tumour characteristics.
Implications of all the available evidence
In comparison with standard schedules for adjuvant 
anthracycline and taxane chemotherapy, the use of more 
dose-intense schedules further reduces the risk of breast cancer 
recurrence or death without increasing mortality from other 
causes. If chemotherapy is to be given, a dose-intense regimen 
should at least be considered.
See Online for appendix
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(B2) Sequential vs concurrent anthracycline and taxane usage (but some difference in drugs between arms)
00) Pfizer USA§
04F GEICAM 2003−10 Spain
(C) Shorter interval between cycles and sequential anthracycline and taxane usage (χ25=8·9; p>0·1; NS)
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Statistical analysis
Statistical methods (stratified log-rank analyses and 
Kaplan-Meier graphs) were as described in previous 
EBCTCG reports.1,13–16 Time-to-event analyses were strati-
fied by age, ER status, trial, and, except for studies 
including neo adjuvant chemotherapy, nodal status. Each 
analysis compared all women allocated to dose-intense 
chemotherapy versus all allocated standard-schedule 
chemo therapy, regardless of treatment compliance 
(yielding intention-to-treat analyses). Log-rank statistics 
were used to assess treatment effects and to estimate the 
first-event-rate ratio (RR) and its confidence interval 
(95% CI for meta-analyses and 99% CI for individual trials 
or subgroups). Breast cancer mortality RRs were estimated 
from corresponding log-rank analyses of mortality with 
recurrence (obtained by subtracting log-rank analyses of 
mortality without recurrence from those of overall 
mortality, which avoids the need to ascertain which deaths 
after recurrence were from breast cancer).14 For each 
comparison, forest plots and Kaplan-Meier graphs describe 
the separate trials and their results, and subgroup analyses 
explore whether pro portional risk reductions depend 
on patient or tumour-related characteristics. Statistical 
analyses used in-house Fortran programs.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the re port. 
The secretariat had access to all data. The writing 
committee was responsible for the decision to submit for 
publication.
Results
33 relevant trials of dose-intense versus standard-schedule 
chemotherapy were identified; individual patient-level 
data were provided for 26 trials, comprising 37 298 (93%) of 
40 070 women. Patients were treated between 1985 and 
2011. Median follow-up was 7·4 years (IQR 5·9–10·3). 
Excluding neo adjuvant trials (n=2583), nodal status was 
known for 33 937 (98%) of 34 715 women. Tumour grade 
was known for 22 840 (61%) women, oestrogen-receptor 
(ER) status for 35 929 (96%), HER2 status for 18 673 (50%), 
and Ki-67 status for 6963 (19%). No gene-expression 
profiles were available.
Figure 1 shows, for each trial, year started, study name, 
regimens compared, the ratio of dose intensities (mg/m² 
per week of anthracycline and, if used, taxane), numbers 
of recurrences, and log-rank analyses, and gives 
combined results for various trial groupings by summing 
the trial-specific log-rank statistics. The appendix 
(pp 3–10) gives similar analyses for distant recurrence at 
any time, local recurrence as first event, contralateral 
breast cancer as first event, breast cancer mortality, death 
without recurrence (first year only, all years), and all-
cause mortality. Combining the recurrence results for all 
26 trials to test for some effect of dose intensification, the 
RR was 0·86 (95% CI 0·82–0·89, p<0·0001).
The trials are grouped by how dose intensification was 
achieved. Groups A1–3 are the dose-dense trials, in which 
the dose-intense treatment arm had a shorter interval 
between cycles than the standard-schedule arm. Group 
A1 trials gave the same chemotherapy drugs, same doses, 
and same number of cycles in both arms, whereas group 
A2 trials gave additional drugs in the control arm, and 
group A3 trials gave additional treatment in the dose-
dense arm. Groups B1–2 are the sequential versus 
concurrent trials, in which the dose-intense arm received 
anthracycline and taxane sequentially, allowing a higher 
dose per cycle of one or, generally, both agents. Group B1 
trials used the same drugs and the same 3-weekly time 
intervals between cycles in both arms, whereas in B2 
there were some differences in drugs between arms. 
Finally, group C trials used both methods of increasing 
dose intensity (shorter interval between cycles and 
sequential anthracycline and taxane usage), and group D 
trials gave higher doses per cycle in fewer cycles.
In group A1 (trials of 2-weekly versus 3-weekly 
chemotherapy cycles using the same drugs and doses), 
individual patient datasets were provided for seven of 
the eight relevant trials, comprising 10 004 (99%) of 
10 132 women randomised. The average weekly dose 
of anthracycline (and taxane, if used) in the dose-dense 
arm was 1·5 times that in the standard-schedule arm. All 
trials included at least three anthracycline-containing 
cycles (minimum total dose 240 mg/m² doxorubicin 
or 360 mg/m² epirubicin). Three trials (comprising 
4109 women) also included paclitaxel at 175 mg/m². 
Growth factors were administered as primary pro-
phylaxis in the 2-weekly cycles and in some studies were 
permitted, if clinically indicated, in the 3-weekly cycles.  
The cumulative risks of recurrence, breast cancer 
mortality, death without recurrence, and death from any 
cause in these seven trials are shown in figure 2. The 
10-year risk of recurrence was 24·0% in the dose-dense 
arm and 28·3% in the standard-schedule arm (RR 0·83, 
95% CI 0·76–0·91; p<0·0001). Exclusion of two studies 
(GONO and Pisa/Genoa) that used lower doses of 
anthracycline than are currently standard did not affect 
the risk reduction (18% without these studies vs 17% with 
Figure 1: Recurrence in trials testing dose-intense strategies versus standard 
scheduling
Taxanes: D=docetaxel. P=paclitaxel. Anthracyclines: A=doxorubicin. E=epirubicin. 
Other: C=cyclophosphamide. Cap=capecitabine. F=fluorouracil. M=methotrexate. 
Bev=bevacizumab (mg/kg). AC=A60C600. EC=E90C600. ADC=A50D75C500.
CMF=classical CMFd1d8. Chemotherapy doses are in mg/m². q2=2-weekly. 
q3=3-weekly. q4=4-weekly. × 14=days 1–14 orally. × 2=day 1, day 8. 
2p=two-sided p value. *For balance, the 75 control patients in the two 3-way 
trials count twice in subtotal (C) and in final total of events/patients. NSABP B-38 
trial assumes a 2:1 dose equivalence ratio for P to D. †Primary prophylaxis with 
colony-stimulating growth factors. ‡Pre-operative chemotherapy: patients in 
these trials were analysed as having unknown nodal status. §Seven trials with no 
data do not contribute to subtotals or to the overall total. Semicolon indicates 
treatment sequence. First column shows study name and year started. χ2 tests in 
section headers are for heterogeneity between trials.  
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these studies; RR 0·82, 95% CI 0·75–0·91; p<0·0001).
The proportional reductions were similar for recurrence, 
breast cancer mortality (RR 0·86, 95% CI 0·77–0·96; 
p=0·0054), and all-cause mortality (0·88, 0·80–0·97; 
p=0·007). There was little or no difference in non-
breast-cancer mortality (18 deaths vs 13 deaths in 
year 0 and 137 vs 144 later).
The proportional reduction in recurrence was similar 
for ER-negative and ER-positive tumours (RR 0·82, 
95% CI 0·71–0·95 vs 0·83, 0·75–0·93). Likewise, nodal 
status and grade did not significantly affect the recurrence 
RR, although few patients had node-negative or low-grade 
cancers (appendix pp 11–12).
In comparisons A2 and A3 (2-weekly versus 3-weekly 
or 4-weekly cycles, but with additional drugs in the 
control or in the dose-dense arm), data were available 
from five of seven relevant trials, comprising 
5508 (84%) of 6575 patients. Three trials had a 2-weekly 
versus 3-weekly taxane component (one paclitaxel, 
two docetaxel). As might be expected, the recurrence 
RR appeared somewhat less extreme in trials with extra 
drugs in the control arm (RR 0·89, 95% CI 0·76–1·03) 
than in trials with higher doses or extra drugs in the 
dose-dense arm (0·79, 0·67–0·92). Combining all trials 
of dose-dense versus standard-schedule chemotherapy 
(A1–3, n=15 512) yielded results similar to those in 
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Figure 2: Dose-dense (2-weekly) chemotherapy versus the same chemotherapy given 3-weekly
10-year cumulative risk of any recurrence (A), breast cancer mortality (B), death without recurrence (C), and all-cause mortality (D). Of the 10 004 women, 71% are N+. RR=rate ratio.
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Figure 3: 10-year risk of any recurrence (left) and breast cancer death (right) for all trials (confounded and unconfounded)
(A) Dose-dense (2-weekly) versus standard schedule (3-weekly) chemotherapy. Of the 15 512 women, 65% are N+. (B) Sequential versus concurrent chemotherapy (both 3-weekly). Of the 11 028 women, 
91% are N+. (C) Sequential (2-weekly) versus concurrent (3-weekly) therapy. Of the 6532 women, 90% are N+.
Allocation
Dose-dense
Standard schedule
Rate ratio (95% CI) from
(O–E)/V
0 5 10
Years 0–4
3·93 (1306/33 239)
4·79 (1569/32 772)
0·82 (0·75–0·89)
−129·2/642·9
Years 5–9
2·31 (333/14 428)
2·52 (355/14 065)
0·89 (0·74–1·04)
−18·2/158·6
Years ≥10
1·11 (29/2604)
1·10 (29/2628)
1·12 (0·54–1·70)
1·5/12·8
Years 0–4
2·09 (1·94–2·24)
2·44 (2·28–2·60)
0·85 (0·76–0·94)
–60·0/368·6
Years 5–9
2·02 (1·80–2·24)
2·26 (2·02–2·49)
0·87 (0·72–1·02)
–21·9/157·5
Years ≥10
1·39 (0·96–1·83)
1·53 (1·08–1·98)
0·94 (0·52–1·37)
–1·2/19·8
0
10
20
30
40
50
Re
cu
rre
nc
e 
(%
)
0 5 10
0
10
20
30
40
50
Br
ea
st
 ca
nc
er
 m
or
ta
lit
y 
(%
)
Allocation
Dose-dense (95% CI)
Standard schedule (95% CI)
Rate ratio (95% CI) from
(O–E)/V
A Any recurrence (15 512 women) Breast cancer mortality (15 512 women)
Recurrence rate per year (%) and log-rank analyses Death rate per year (%) (total rate − rate in women without recurrence) and log-rank analyses
Dose-dense
Standard schedule
30·5%
21·0%
RR 0·84 (95% CI 0·78–0·90)
Log-rank 2p<0·0001
10-year gain 4·4% (95% CI 2·6 to 6·3) 
26·1%
20·9%
18·1%
17·7%
RR 0·86 (95% CI 0·79–0·93)
Log-rank 2p=0·0004
10-year gain 2·9% (95% CI 1·2 to 4·6) 
11·7%
10·0%
Allocation
Sequential 3-weekly
Concurrent 3-weekly
Rate ratio (95% CI) from
(O–E)/V
0 5 10
Years 0–4
3·83 (917/23 937)
4·30 (1025/23 819)
0·88 (0·79−0·97)
−57·7/451·5
Years 5–9
2·72 (244/8956)
3·24 (281/8684)
0·84 (0·68−1·00)
−21·4/125·6
Years ≥10
2·58 (16/621)
3·75 (22/587)
0·62 (0·10−1·14)
−4·3/9·0
0
10
20
30
40
50
Re
cu
rre
nc
e 
(%
)
0 5 10
Years 0–4
1·98 (1·80–2·15)
2·12 (1·94–2·30)
0·92 (0·80–1·04)
–21·5/243·9
Years 5–9
1·96 (1·69–2·24)
2·37 (2·07–2·67)
0·83 (0·66–1·01)
–18·8/103·6
Years ≥10
2·21 (1·13–3·29)
2·37 (1·25–3·50)
0·91 (0·25–1·58)
−0·7/7·9
0
10
20
30
40
50
Br
ea
st
 ca
nc
er
 m
or
ta
lit
y 
(%
)
Allocation
Sequential 3-weekly (95% CI)
Concurrent 3-weekly (95% CI)
Rate ratio (95% CI) from
(O–E)/V
B Any recurrence (11 028 women) Breast cancer mortality (11 028 women)
Recurrence rate per year (%) and log-rank analyses Death rate per year (%)  (total rate − rate in women without recurrence) and log-rank analyses
Sequential 3-weekly
Concurrent 3-weekly
31·3%
19·5%
RR 0·87 (95% CI 0·80–0·94)
Log-rank 2p=0·0006
10-year gain 3·2% (95% CI 0·8 to 5·6) 
28·1%
19·8%
17·7%
17·4%
RR 0·89 (95% CI 0·80–0·99)
Log-rank 2p=0·030
10-year gain 2·1% (95% CI 0·1 to 4·1) 
10·3%
9·5%
Allocation
Sequential 2-weekly
Concurrent 3-weekly
Rate ratio (95% CI) from
(O–E)/V
0 5 10
Years 0–4
4·61 (643/13944)
5·64 (744/13185)
0·80 (0·70–0·90)
–69·7/310·9
Years ≥5
2·82 (183/6495)
3·03 (173/5702)
0·90 (0·70–1·11)
–8·6/82·5
0
10
20
30
40
50
Re
cu
rre
nc
e 
(%
)
0 5 10
Years 0–4
2·43 (2·18–2·68)
2·86 (2·58–3·13)
0·83 (0·69–0·96)
–33·9/179·3
Years ≥5
2·59 (2·23–2·96)
3·19 (2·76–3·62)
0·80 (0·62–0·98)
–21·2/95·7
0
10
20
30
40
50
Br
ea
st
 ca
nc
er
 m
or
ta
lit
y 
(%
)
Allocation
Sequential 2-weekly (95% CI)
Concurrent 3-weekly (95% CI)
Rate ratio (95% CI) from
(O–E)/V
C Any recurrence (6532 women) Breast cancer mortality (6532 women)
Recurrence rate per year (%) and log-rank analyses Death rate per year (%) (total rate − rate in women without recurrence) and log-rank analyses
Sequential 2-weekly
Concurrent 3-weekly
35·0%
24·4%
RR 0·82 (95% CI 0·74–0·90)
Log-rank 2p<0·0001
10-year gain 4·6% (95% CI 1·1 to 8·1) 30·4%
26·1%
22·1%
20·2%
RR 0·82 (95% CI 0·73–0·92)
Log-rank 2p=0·0009
10-year gain 4·0% (95% CI 0·6 to 7·5) 
13·6%
11·5%
Years Years
Articles
1446 www.thelancet.com   Vol 393   April 6, 2019
figure 2, but with narrower confidence intervals 
(recurrence RR 0·84, 95% CI 0·78–0·90; p<0·0001; 
breast cancer mortality 0·86, 0·79–0·93; p=0·0004; 
figure 3A; appendix p 13).
In group B1 (sequential versus concurrent anthracycline 
and taxane scheduling, with no difference in other 
drugs), information was available from five of seven trials, 
comprising 9644 (93%) of 10 402 women. These trials 
compared six to eight cycles of 3-weekly treatment with 
an anthracycline (usually doxorubicin) followed by a 
taxane (all single-agent docetaxel) versus four to six cycles 
of 3-weekly treatment with the same agents given 
concurrently. The dose-intensity ratio achieved by giving 
drugs sequentially ranged from 1·0 to 1·5, with a 
weighted average of 1·23 for anthracycline and 1·32 for 
docetaxel, and there was a 13% proportional reduction in 
recurrence (RR 0·87, 95% CI 0·80–0·95; p=0·0016). This 
recurrence reduction was unchanged when groups B1 
and B2 were combined (figure 3B).
Group C comprises the trials that increased dose 
intensity both by giving 2-weekly rather than 3-weekly 
treatment and by sequential rather than concurrent 
anthracycline and taxane usage; information was available 
from all six such studies (n=6532). By combining the two 
dose-intensification methods, the ratio of anthracycline 
dose intensities in the dose-intense arm to that in the 
standard-schedule arm ranged from 1·5 to 2·5 (figure 1), 
averaging 2·0 for anthracycline and 1·8 for taxane. The 
taxane used in three of these trials was paclitaxel, two used 
docetaxel, and one used paclitaxel (175 mg/m²) in the 
dose-intense arm but docetaxel (75 mg/m²) in the control 
arm. There was an 18% reduction in recurrence (RR 0·82, 
95% CI 0·74–0·90; p<0·0001; figure 3C), again favouring 
the more dose-intense treatment schedule.
In group D, two trials (n=4226) achieved a dose-
intensity ratio of 1·5 by administering a 50% higher dose 
of anthracycline per cycle for four rather than six cycles. 
The effect on recurrence rates was not significant 
(RR 0·93, 95% CI 0·84–1·04; p=0·19), but also did not 
differ significantly from that in the other groups of trials.
Despite substantial variation in chemotherapy schedules 
and trial designs, rate ratios for recurrence for all seven trial 
groupings shown in figure 1 consistently favoured the 
more dose-intense treatment arm (p=0·52 for hetero-
geneity between subtotals). Combining data from all 
37 298 women in the 26 dose-intensification studies, the 
10-year risk of recurrence for the dose-intense treatment 
arms was 28·0% compared with 31·4% for standard 
treatment (gain of 3·4%, 95% CI 2·2–4·5; p<0·0001), with 
similar improvements in breast cancer mortality (18·9% vs 
21·3%; gain of 2·4%, 1·3–3·4; p<0·0001), and all-cause 
mortality (22·1% vs 24·8%; gain of 2·7%, 1·6–3·8; 
p<0·0001; figure 4). These average findings are further 
subdivided in the appendix (pp 16–21).
Unexpectedly, the 10-year risk of death without re-
currence appeared to be somewhat lower in the dose-
intense arms than in the standard-schedule arms 
(4·1% vs 4·6%; figure 4C), although this difference 
was only of borderline significance (RR 0·88, 95% CI 
0·78–0·99; p=0·034). Of the deaths without recorded 
recurrence, half were from an unknown cause, but these 
were equally divided between dose-intense and control 
arms (264 [1·4%] of 18 623 vs 278 [1·5%] of 18 750; 
appendix p 22). Additionally, deaths without recurrence 
were unrelated to tumour size or nodal involvement 
(appendix p 23), suggesting that most were not mis-
classified breast cancer deaths.
There was borderline significant (p=0·012) hetero geneity 
between results of the 26 trials for recurrence (figure 1). 
Subgroup analyses (appendix pp 14–15) explored whether 
this heterogeneity might be explained by differences in the 
numbers of dose-intense treatment cycles or inclusion of a 
dose-dense versus standard taxane comparison. In the 
trials with six to eight cycles of 2-weekly versus 3-weekly 
treatment, 2-weekly chemo therapy was significantly better 
than standard schedule chemotherapy in preventing 
recurrence both for anthracycline-based regimens 
(RR 0·83, 95% CI 0·73–0·95; p=0·0056) and for regimens 
containing anthracycline plus taxane (0·78, 0·71–0·87; 
p<0·0001). By contrast, in the trials with only three to 
four accelerated cycles, reductions in recurrence were not 
significant regardless of whether taxanes were included or 
not, although the confidence intervals were wide (RR 0·84, 
95% CI 0·63–1·13 with a taxane vs 0·94, 0·82–1·09 
without a taxane). After combining all trials of dose 
intensification of anthracycline regimens without a taxane 
dose-intensification component, including those in group 
D, the recurrence reduction for such regimens remained 
significant (RR 0·90, 95% CI 0·84–0·97; p=0·005).
To increase the statistical power to investigate whether 
proportional risk reductions vary by other factors, 
subgroup analyses (figure 5; appendix p 16) included 
all women in all trials. The proportional recurrence 
reduction was highly significant in years 0–1 (RR 0·83, 
99% CI 0·76–0·92; p<0·0001) and in years 2–4 (0·84, 
0·77–0·92; p<0·0001). The reduction was less definite 
in years 5–9 (RR 0·91, 99% CI  0·81–1·03; p=0·049) and 
there were few events thereafter. Distant recurrence 
(RR 0·87, 95% CI 0·84–0·91; p<0·0001), local recur-
rence (0·79, 0·71–0·88; p<0·0001), and new contralateral 
breast cancer (0·77, 0·65–0·91; p=0·0028) were all 
reduced (appendix p 17).
Subgroup analyses of recurrence and breast cancer 
mortality by age, tumour size, nodal status, ER and PR 
status, HER2 status, grade, tumour proliferation (Ki-67), 
and histological type showed similar proportional risk 
reductions with no significant heterogeneity (figure 5; 
appendix pp 16–21). Although the proportional recurrence 
reduction was similar in ER-negative and ER-positive 
breast cancer, the absolute reduction in 10-year recurrence 
was somewhat larger for ER-negative disease than for 
ER-positive disease (3·7% vs 3·1%; figure 6). For women 
with node-positive disease, those with four or more 
involved nodes had substantially worse prognosis than did 
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those with one to three involved nodes; the joint depen-
dence of treatment outcome on ER status and the degree 
of nodal involvement is given in the appendix (p 20).
There was no increase in deaths without recorded 
recurrence during the first year after randomisation 
(0·3% in the dose-intense arm vs 0·4% in the standard 
arm, p=0·053; appendix p 22). There was no difference 
in deaths from cardiovascular disease (17 vs 18, p=0·92), 
from acute myeloid leukaemia (33 vs 27; p=0·53), or from 
other cancers (56 vs 66; p=0·27; appendix p 22). Few 
deaths due to toxicity were reported in trial publications, 
and numbers did not differ significantly between dose-
intense and standard treatment schedules.
Recording of toxicity within each trial varied considerably, 
so individual patient-level data on non-fatal toxicity were 
not requested. Adverse events reported in trial publications 
are, however, summarised in the appendix (pp 24–30). For 
the 2-weekly dose-dense chemotherapy schedules, primary 
prophylaxis with G-CSF was mandated in all trials, leading 
to lower levels of grade 3–4 neutropenia and neutropenic 
sepsis than in control arms. There were, however, higher 
levels of grade 3–4 anaemia in the dose-intense arms of 
some trials. There was no consistent difference in 
cardiotoxicity or other reported non-haematological toxicity 
between dose-intense and control arms. There was a 
moderate increase in the proportion of patients who did 
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Figure 4: Pooled analysis of all dose-intensification trials
10-year cumulative risk of any recurrence (A), breast cancer mortality (B), death without recurrence (C), all-cause mortality (D), for dose-intense versus standard schedule arm. Of the 37 298 women, 
77% are N+. RR=rate ratio.
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Figure 5: Subset analyses of pooled data from all dose-intensification trials; any first recurrence (including locoregional recurrence, distant recurrence, and 
new contralateral disease)*
ER=oestrogen receptor. PR=progesterone receptor. NS=not significant. *For balance, the 75 control patients in 3-way trials count twice in numbers of events/
patients. Unless otherwise specified, patients whose category is unknown are omitted. Unless specified as for trend, χ2 tests are for heterogeneity.
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not complete all cycles of chemotherapy in the dose-
intense compared with standard-schedule arms (11·9% vs 
9·2%, p<0·0001; appendix p 33), which was mainly 
explained by patients failing to complete the final courses 
of the longer sequential therapy regimens. Compliance 
was similar in both arms in the trials comparing 2-weekly 
versus 3-weekly chemotherapy using the same drugs, 
doses, and number of cycles.
Discussion
This meta-analysis demonstrates that increasing the 
dose intensity of anthracycline and taxane-based 
adjuvant chemotherapy regimens for early breast 
cancer, either by shortening the interval between cycles 
or by sequential administration of anthracyclines and 
taxanes (allowing full-dose treatment with each agent), 
reduces the 10-year risk of recurrence and of death from 
breast cancer by about 10–15%. This reduction is only 
moderate but since the standard chemotherapy com-
parator is already known to reduce the risk of breast 
cancer death by about a third,1 preventing a further 
10–15% of deaths would imply that, compared to no 
chemotherapy, dose-intense adjuvant chemotherapy 
schedules with anthracycline and taxane could prevent 
Figure 6: 10-year recurrence (A) and breast cancer mortality (B) by oestrogen receptor status
Pooled data from all trials of dose intense versus standard schedule chemotherapy. Of the 10 900 women who are oestrogen receptor (ER)-negative, 66% are N+; and of the 25 029 women who are 
ER-positive, 84% are N+.
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about 40% of deaths from breast cancer during the 
first decade.
The 26 trials included in this meta-analysis varied 
substantially in the chemotherapy combinations and in 
the scheduling used to achieve greater dose intensity. 
Although this complicates the meta-analysis, the risk 
reductions were remarkably consistent, with an absolute 
reduction of about 3% in the 10-year risk of breast cancer 
mortality in the trials comparing 2-weekly versus 
3-weekly chemotherapy cycles, in those of sequential 
versus concurrent anthracycline and taxane schedules, 
and in those adopting both strategies, with similar results 
regardless of whether or not the analyses included the 
trials with additional drugs or additional cycles given in 
one arm but not the other.
Heterogeneity between the trial designs makes it difficult 
to identify reliably more or less effective dose-intensification 
strategies. Despite limited power to detect any real 
differences in treatment effects between trial groupings, 
the largest proportional reduction in breast cancer mortality 
was seen in the group of trials that used both 2-weekly 
and sequential scheduling, which also achieved the 
highest dose-intensity ratios. The smallest proportional 
reduction was in the sequential versus concurrent 3-weekly 
scheduling trial group, in which the dose intensity ratio 
was lowest. In individual trials, the largest risk reductions 
were generally seen in those with the largest dose-intensity 
ratios (eg, MA.21,18 AGO,19 and ETC20).
The risk reduction appeared to be smaller in trials with 
fewer dose-dense cycles than in those with six or more 
dose-dense cycles, regardless of whether they included an 
accelerated taxane as well as anthracycline component. The 
largest trial, TACT2,21 compared 2-weekly versus 3-weekly 
scheduling for only the first four cycles of single-agent 
epirubicin and achieved one of the smallest risk reductions. 
The risk reduction with sequential chemo therapy also 
appeared somewhat lower in trials with six cycles of 
concurrent chemotherapy in the control arm (BCIRG 00522 
and NSABP B-382) than in those with just four cycles 
(AGO,19 BIG 02–98,23 and NSABP B-3024). Similarly, 
somewhat greater benefit from dose intensi fication was 
seen in MA.21,18 which compared six 2-weekly cycles in the 
dose-intense arm with four 3-weekly cycles in the control 
arm. These findings are consistent with a previous 
EBCTCG meta-analysis of adding a taxane to anthracycline-
based chemotherapy in which longer treatment in the 
anthracycline control group appeared to negate the benefits 
of adding a taxane.1 By contrast, inclusion of fluorouracil 
(PANTHER25) or cyclophosphamide (GeparDuo26) in the 
standard but not the dose-intensive schedule did not seem 
important, consistent with trials of adding these agents to 
anthracycline regimens.23,24,27
Five of the dose-dense versus standard taxane com-
parisons involved paclitaxel (175 mg/m²), given 2-weekly 
versus 3-weekly. Currently, paclitaxel is usually given 
once weekly at 80 mg/m² as this schedule was found to 
be superior to 3-weekly paclitaxel at 175 mg/m² in the 
intergroup E1199 trial,28 perhaps because it involved a 
higher dose intensity (80 mg/m² per week vs 58 mg/m² 
per week). This explanation is supported by the 
SWOG S0221 study,17 which found similar outcomes with 
once-weekly paclitaxel (80 mg/m²) and 2-weekly paclitaxel 
(175 mg/m²), the regimen tested in many trials in our 
meta-analysis in which the dose intensity is comparable. 
Moreover, because trials of docetaxel also showed 
significant benefit from dose intensification (eg, all of the 
trials of sequential versus concurrent scheduling in 
section B1 of figure 1 used docetaxel), as did trials with no 
taxane dose intensification, a better outcome with more 
dose-intense chemotherapy cannot be accounted for 
solely by the frequency of paclitaxel administration.
Our meta-analysis therefore suggests that increasing 
the dose intensity of taxane administration is likely to 
enhance efficacy irrespective of the agent used or the 
frequency of administration. We did not identify any trials 
assessing dose-intensification of taxane regimens without 
anthracycline, such as the now widely used docetaxel-
cyclophosphamide combination. Although our findings 
suggest that giving this combination 2-weekly instead of 
the usual 3-weekly administration might enhance efficacy, 
this would need to be confirmed in randomised trials.
The reduction in new primary contralateral breast cancer 
was unexpected as no significant reduction in contralateral 
breast cancer was reported in previous EBCTCG meta-
analyses of anthracycline chemotherapy versus no chemo-
therapy, or in trials of the addition of taxane to anthracycline 
chemotherapy.1 However, in both those meta-analyses 
there was a borderline significant reduction in contralateral 
disease in the first 5 years, with no further benefit 
thereafter. This is consistent with the reduction in new 
contralateral breast cancer seen in years 0–4 with dose-
intense compared to standard schedule chemotherapy 
(appendix p 17), with no significant additional benefit 
thereafter, which might be explained by chemotherapy 
eradicating or delaying the emergence of subclinical 
contralateral breast cancers but having little impact on the 
development of future contralateral disease.
Subgroup investigations did not identify any individual 
patient or tumour characteristic that predicted greater or 
lesser proportional benefit from dose-intense treatment. 
In particular, the proportional reductions in recurrence 
were similar in ER-positive and ER-negative disease. The 
proportional recurrence reductions were also similar for 
N1–3 and N4+ disease and appeared to be similar in node-
negative disease, although comparatively few women 
with node-negative disease were enrolled in these trials. 
This is consistent with other chemotherapy comparisons.1 
Similarly, although only 50% of patients had known 
HER2 status, and use of trastuzumab was not routine in 
some trials, there was no indication that treatment 
efficacy differed by HER2 status. Also, there was no trend 
towards increasing benefit with increasing proliferation, 
as assessed by Ki-67. Too few patients aged older than 
70 years, or with low-grade disease, were entered in these 
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trials to directly assess the benefits of dose-intensification 
in these subgroups.
There was no indication of any increase in death without 
recurrence with dose intensification, overall or during the 
period when chemotherapy was administered. No increase 
in cardiovascular mortality or deaths from haematological 
malignancies was apparent in patients who received dose-
intense treatment, although information on cause of death 
was incomplete, and longer follow-up is needed to evaluate 
fully the comparative benefits and risks of dose intensi-
fication. Individual patient data on non-fatal toxicity 
were not collected but trial publications suggest only 
minor differences between dose-intense and standard 
chemotherapy. The selective use of colony-stimulating 
growth factors in the dose-intense treatment arm compli-
cates comparisons of haematological toxicity between 
treatments, with leucopenia recorded less frequently with 
dose-intense treatment. Trials that evaluated patient-
reported outcomes found overall quality of life to be worse 
during dose-intense treatment than during standard 
schedule treatment, but similar quality of life after the 
treatment phase ended.21,22,25,29,30
The balance of benefit versus toxicity, therefore, appears 
to favour more dose-intense chemotherapy. A further 
advantage of 2-weekly versus 3-weekly chemotherapy—but 
not of sequential versus concurrent chemotherapy—is that 
treatment is completed sooner. As the proportional 
reductions in recurrence with dose-intense chemotherapy 
did not differ significantly by any measured tumour 
characteristic, these findings are applicable to most women 
who are offered chemotherapy. The present findings are of 
limited relevance to the question of which women with 
early breast cancer should be offered chemotherapy, 
although they do indicate that chemo therapy can reduce 
breast cancer mortality rates by 40% rather than a third. 
The absolute gain from this proportional reduction in 
recurrence depends chiefly on what the risk of distant 
recurrence would be without chemotherapy, which varies 
greatly from one woman to another, and is the subject of 
much ongoing research. The findings are, however, directly 
relevant to selection of what regimen to use, and they show 
that, if chemotherapy is to be given, a dose-intense regimen 
should at least be considered.
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